Related Experiment Videos
Correlation of prostate-specific antigen and technetium-99m HMDP bone imaging
W J Shih1, B Wierzbinski, J Collins
1VA Medical Center, Lexington, Kentucky.
Clinical Nuclear Medicine
|October 1, 1989
Summary
Prostate-specific antigen (PSA) measurements aid in diagnosing prostate cancer metastasis. Elevated PSA levels correlate with bone metastases, enhancing bone imaging interpretation and clinical monitoring for patients with prostate carcinoma.
Area of Science:
- Oncology
- Biochemistry
Background:
- Prostate-specific antigen (PSA) is a biomarker used in prostate cancer management.
- Bone imaging is crucial for detecting skeletal metastases in cancer patients.
- The clinical utility of PSA in conjunction with bone imaging requires further evaluation.
Purpose of the Study:
- To evaluate the clinical utility of prostate-specific antigen (PSA) measurements.
- To assess the role of PSA in enhancing bone imaging interpretation for prostate carcinoma.
- To determine if PSA levels can help identify the origin of bone metastases.
Main Methods:
- PSA levels were measured using a monoclonal immunoradiometric assay.
- 32 prostate carcinoma patients and 13 nonprostate carcinoma patients were included.
- Patients underwent simultaneous PSA measurements and bone imaging.
Main Results:
- Nonprostate carcinoma patients with bone metastases had normal PSA levels.
- Prostate cancer patients with elevated PSA (≥4 ng/ml) showed a higher incidence of bone metastases.
- PSA levels correlated with the progression, regression, or stability of bone lesions in prostate cancer patients.
Conclusions:
- PSA measurements significantly enhance the interpretation of bone imaging in prostate carcinoma.
- PSA serves as a valuable tool for the clinical monitoring of prostate cancer.
- PSA testing can definitively identify prostate carcinoma as the primary source of bone metastases.